ClinicalTrials.gg
CompletedNCT03726658AGN-241751Updated Apr 7, 2026Results posted

Zelquistinel in the Treatment of Adults With Major Depressive Disorder

A Phase 1/2 interventional study of AGN-241751 and Placebo in Major Depressive Disorder, sponsored by Syndeio Biosciences, Inc. Completed at 5 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Syndeio Biosciences, Inc · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.

Enrollment
323rd of 1,323
226 · median 70
Started
2018
with 49 others
Phase 1/2
32 of 1,500
6 open now
Registered
963rd of 1,500
by date

Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 323rd largest by enrollment of the 1,323 interventional ones that give a count, is one of 50 that started in 2018, is one of 32 in phase 1/2, and was the 963rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:

210 more — sign in →

All 215 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,500 studies in Depressive Disorder, Major with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of AGN-241751 in participants with Major Depressive Disorder

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written from the participant has been obtained prior to any study-related procedures
  • Meet (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria (American Psychiatric Association, 2013). for MDD (based on confirmation from the modified SCID), with a current major depressive episode of at least 8 weeks and not exceeding 18 months in duration at Visit 1.
  • Have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test at screening (Visit 1) if a (Women of Childbearing Potential).
  • Female participants willing to minimize the risk of becoming pregnancy for the duration of the clinical study and follow-up period. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • Not a WOCBP (Women of Childbearing Potential). OR
  • A WOCBP (Women of Childbearing Potential). who agrees to follow the guidance in during the treatment period and for at least 4 to 5 weeks after the last dose of study treatment.
  • Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. A male participant must agree to use contraception during the treatment period and for at least 10 weeks after the last dose of study treatment and refrain from donating sperm during this period.
  • Able, as assessed by the investigator, and willing to follow study instructions and likely to complete all required study visits.

Exclusion criteria

Exclusion Criteria:

Psychiatric and Treatment-Related Criteria

  • (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) based diagnosis of any disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1. Comorbid generalized anxiety disorder, social anxiety disorder, or specific phobias are acceptable provided they play a secondary role in the balance of symptoms and are not the primary driver of treatment decisions.
  • Lifetime history of meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition)criteria for:
  • Schizophrenia spectrum or other psychotic disorder
  • Bipolar or related disorder
  • Major neurocognitive disorder
  • Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study
  • Dissociative disorder
  • Posttraumatic stress disorder
  • MDD with psychotic features
  • History of meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) criteria for alcohol or substance use disorder (other than nicotine or caffeine) within the 6 months before Screening (Visit 1).
  • History (based on participant report and/or medical records, and investigator judgment) of the following:
  • Inadequate response to ECT, a monoamine oxidase inhibitor, ketamine, or adjunctive treatment with an antipsychotic
  • Treatment with clozapine or any depot antipsychotic
  • ECT, vagus nerve stimulation, transcranial magnetic stimulation, or any experimental central nervous system treatment during the current episode or in the 6 months before Screening (Visit 1) whichever is longer)
  • Tardive dyskinesia, serotonin syndrome, or neuroleptic malignant syndrome
  • Having received:
  • Anticonvulsant/mood stabilizer, within 1 year prior to Screening (Visit 1)
  • Antipsychotic in the current episode, with the exception of quetiapine given for insomnia ≤ 50 mg/day provided it can be safely discontinued prior to Visit 2
  • Combination therapy of more than 2 ADTs in the current episode if given for depression at adequate dose and duration
  • ADT augmentation agent in the current episode
  • Lifetime history of nonresponse to ≥ 2 antidepressants after adequate trials (adequate treatment is defined as at least 6 weeks at an adequate dose(s) based on approved package insert recommendations).
  • Positive result at Screening (Visit 1) from the UDS (Urine Drug Screen) test for any prohibited medication. Exception: Participants with a positive UDS (Urine Drug Screen) at Screening for opiates, cannabinoids, or episodic use of benzodiazepines may be allowed in the study provided:
  • The drug was used for a legitimate medical purpose;
  • The drug can be safely discontinued prior to participation in the study (except for episodic use of benzodiazepines which may be continued); and
  • A repeat UDS is negative for these substances prior to enrollment (except for episodic use of benzodiazepines which may be continued)
  • Part B participants who have regularly been using benzodiazepines (even for legitimate medical purposes) for more than 2 months should not be included in the study if there is doubt that the medication can be safely discontinued during screening.
  • A suicide attempt within the past year
  • Prior participation in any study of AGN-241751
  • Initiation or termination of psychotherapy for depression within the 3 months preceding Screening (Visit 1), or plans to initiate, terminate, or change such therapy during the course of the study. (Support meetings or counseling [eg, marital counseling] are allowed provided they are no more frequent than weekly and do not have treatment of depression as their objective.)
  • Ongoing treatment with phototherapy, or termination of phototherapy within 1 month of Visit 1.
  • Known allergy or sensitivity to the study medication or its components.
  • Hypothyroidism or hyperthyroidism, unless stabilized on appropriate pharmacotherapy with no change in dosage for at least 1 month before Screening (Visit 1)
  • History of seizure disorder, stroke, significant head injury, tumor of the central nervous system, or any other condition that predisposes to seizure.
  • Known infection
  • Part B: Previously diagnosed hearing loss; current hearing aid users (within the last 6 months), or history of gross hearing loss, such as conductive hearing loss, congenital hearing loss, sudden hearing loss, hearing loss due to recent noise or occupational exposure.
  • Current enrollment in an investigational drug or device study or participation in such a study within 6 months of entry into this study (or within 3 months of entry into this study (Part B).
  • Part B: Prior participation in any investigational study of AGN-241751, rapastinel, ketamine, or esketamine. Part B participants should not have participated in Part A at any time, and Part A participants should not have participated in Part B at any time (ie, Part A is not a contingent step to participate in Part B).
  • Employee, or immediate relative of an employee, of the sponsor, any of its affiliates or partners, or the study center
  • Inability to speak, read, and understand the English language sufficiently to understand the nature of the study, to provide written , or to allow the completion of all study assessments.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    AGN-241751 3mg

    AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B

    Drug: AGN-241751

  • Experimental
    AGN-241751 10mg

    AGN-241751, oral administration, once per day

    Drug: AGN-241751

  • Experimental
    AGN-241751 25mg

    AGN-241751, oral administration, once per day in Part A. Twice per day (BID) in Part B

    Drug: AGN-241751

  • Placebo comparator
    Placebo

    Placebo, oral administration, once per day in part A. Twice per day (BID) in Part B

    Drug: Placebo

Interventions

  • AGN-241751 is supplied in tablet form

  • DrugPlacebo

    Placebo is supplied in tablet form

06

What researchers measure

Primary outcomes

  1. Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group

    Efficacy will be measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis

    Time frame: Baseline (Day1) to Day 2

  2. Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose)

    Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.

    Time frame: Baseline (Day 1) to Day 8

Secondary outcomes

  1. Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo

    Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.

    Time frame: Baseline (Day 1) to Day 22

  2. Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group

    Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis

    Time frame: Baseline (Day 1) to Day 21

07

Results

Posted Jul 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneAGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per Day
Started26262625404041
Completed25262425343536
Not completed1020655
Withdrew: Lost to follow-up0020011
Withdrew: Withdrawal by subject1000642
Withdrew: Pregnancy0000001
Withdrew: Not reported0000001

Outcome measures

PrimaryPart A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group

Efficacy will be measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis

Time frame:
Baseline (Day1) to Day 2
Reported as:
Least squares mean · score on a scale
Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group
score on a scaleAGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per Day
Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group-9.4 ± 1.57-6.7 ± 1.58-9.5 ± 1.57-9.3 ± 1.61———
Statistical analysis
  • AGN-241751 3mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.98 (The a priori threshold for statistical significance was P\<0.05.) · Mean difference (final values): -0.1
  • AGN-241751 10mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.25 (The a priori threshold for statistical significance was P\<0.05.) · Median difference (final values): 2.6Change from baseline in treated group compared to change from baseline in placebo group on Day 2 (Day 1 post initial dose).
  • AGN-241751 25mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.93 (Change from baseline in treated group compared to change from baseline in placebo group on Day 2 (Day 1 post initial dose).) · Mean difference (final values): -0.2
PrimaryPart B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose)

Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.

Time frame:
Baseline (Day 1) to Day 8
Reported as:
Least squares mean · score on a scale
Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose)
score on a scaleAGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per Day
Part B: Change From Baseline in MADRS Score at Day 8 Post the Initial Dose of AGN-241751 (i.e. 1 Day After the Seventh Daily Dose)————-12.8 ± 1.53-10.5 ± 1.52-10.9 ± 1.48
Statistical analysis
  • AGN-241751 3mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.43 (a priori threshold for statistical significance was \<0.05) · Mean difference (final values): -1.6
  • AGN-241751 25mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.84 (The a priori threshold for statistical significance was P \<0.05) · Median difference (final values): 0.4
SecondaryPart A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo

Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement.

Time frame:
Baseline (Day 1) to Day 22
Reported as:
Least squares mean · score on a scale
Part A: Change From Baseline in MADRS Score on Day 9 and Day 15 of AGN-241751 Once Daily and at Day 22 (7 Days After Completion of AGN-241751 Dosing) Compared With Change in Placebo
score on a scaleAGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per Day
Day 9-13.0 ± 1.86-13.6 ± 1.87-14.1 ± 1.85-12.0 ± 1.89———
Day 15-13.2 ± 1.86-13.7 ± 1.87-13.2 ± 1.89-11.6 ± 1.90———
Day 22-12.5 ± 1.97-11.8 ± 1.91-14.5 ± 1.90-13.6 ± 1.94———
Statistical analysis
  • AGN-241751 3mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.69 (A priori threshold for statistical significance was P\<0.05.) · Mean difference (final values): -1.1
  • AGN-241751 10mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.44 (The a priori threshold for statistical significance was P\<0.05) · Mean difference (final values): -2.1
  • AGN-241751 25mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.43 (The a priori threshold for statistical significance was P\<0.05) · Mean difference (final values): 2.1
  • AGN-241751 3mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.55 (The a priori threshold for statistical significance was P\<0.05.) · Median difference (final values): -1.1
  • AGN-241751 10mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.44 (The a priori threshold for statistical significance was P\<0.05) · Mean difference (final values): -2.1
  • AGN-241751 25mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.56 (The a priori threshold for statistical significance was P\<0.05) · Median difference (final values): -1.6
  • AGN-241751 3mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.80 (The a priori threshold for statistical significance was P\<0.05.) · Mean difference (final values): 0.7
  • AGN-241751 10mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.45 (The a priori threshold for statistical significance was P\<0.05) · Median difference (final values): -2.1
  • AGN-241751 25mg Daily vs Placebo Daily · Mixed Models Analysis · p = 0.67 (The a priori threshold for statistical significance was P\<0.05) · Mean difference (final values): -1.2
SecondaryPart B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group

Efficacy was measured by improvement in Montgomery-Asberg Depression Rating Scale (MADRS) total score. The MADRS is a clinician-rated scale to assess depressive symptomatology during the preceding week. The MADRS score ranges from 0 to 60 with a higher score indicating greater depression. A negative change score indicates improvement. Results are reported as change from baseline in treated group compared to change from baseline in placebo, reported as least squares difference and (standard error) calculated from a mixed model-repeated measures analysis

Time frame:
Baseline (Day 1) to Day 21
Reported as:
Least squares mean · score on a scale
Part B: Change From Baseline in MADRS Score on Day 11, Day 14, and Day 18 of AGN-241751 Administered Two Times Daily and on Day 21 (7 Days After Completion of Dosing) in Treated Group Compared to Change From Baseline in Placebo Group
score on a scaleAGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per Day
Day 11————-15.8 ± 1.70-15.2 ± 1.72-14.0 ± 1.67
Day 14————-17.0 ± 1.76-15.3 ± 1.82-14.7 ± 1.71
Day 18————-18.3 ± 1.88-15.0 ± 1.98-16.9 ± 1.86
Day 21————-17.3 ± 1.79-16.5 ± 1.84-16.5 ± 1.74
Statistical analysis
  • AGN-241751 3mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.43 (a priori threshold for statistical significance was p\>0.05) · Mean difference (final values): -1.9
  • AGN-241751 25mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.59 (The a priori threshold for statistical significance was P\<0.05) · Mean difference (final values): -1.3
  • AGN-241751 3mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.35 (The a priori threshold for statistical significance was P\<0.05) · Mean difference (final values): -2.3
  • AGN-241751 25mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.82 (The a priori threshold for statistical significance was P\<0.05) · Mean difference (final values): -0.6
  • AGN-241751 3mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.61 · Mean difference (final values): -1.4
  • AGN-241751 25mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.47 (The a priori threshold for statistical significance was P\<0.05) · Median difference (final values): 2.0
  • AGN-241751 3mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.76 · Mean difference (final values): -0.7
  • AGN-241751 25mg Two Times Per Day vs Placebo 2 Times Per Day · Mixed Models Analysis · p = 0.99 (Change from baseline in treated group compared to change from baseline in placebo group on Day 21) · Median difference (final values): 0.0

Adverse events

Collected over Two weeks = 14 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AGN-241751 3mg Daily0/26 (0%)0/26 (0%)6/26 (23.1%)
AGN-241751 10mg Daily0/26 (0%)0/26 (0%)8/26 (30.8%)
AGN-241751 25mg Daily0/26 (0%)0/26 (0%)6/26 (23.1%)
Placebo Daily0/25 (0%)0/25 (0%)3/25 (12%)
AGN-241751 3mg Two Times Per Day0/41 (0%)0/41 (0%)15/41 (36.6%)
AGN-241751 25mg Two Times Per Day0/41 (0%)0/41 (0%)20/41 (48.8%)
Placebo 2 Times Per Day0/41 (0%)1/41 (2.4%)22/41 (53.7%)
Most frequent serious events
Most frequent serious events
EventAGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per Day
Abortion InducedPregnancy, puerperium and perinatal conditions0/260/260/260/250/410/411/41
Most frequent other events
Most frequent other events
EventAGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per Day
HeadacheNervous system disorders4/265/264/263/256/4110/4114/41
NauseaGastrointestinal disorders2/263/262/260/251/416/412/41
ConstipationGastrointestinal disorders0/260/260/260/253/412/413/41
Abnormal DreamsNervous system disorders0/260/260/260/253/412/412/41
Back PainMusculoskeletal and connective tissue disorders0/260/260/260/253/410/411/41

Baseline characteristics

Participants in Part A and Part B were analyzed completely separately.

Age, Continuous
Age, Continuous(years)AGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per DayTotal
Mean44.2 ± 13.1439.0 ± 13.8441.4 ± 15.0336.2 ± 12.4338.5 ± 12.6240.3 ± 14.2137.7 ± 14.0640.2 ± 13.78
Sex: Female, Male
Sex: Female, Male(Participants)AGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per DayTotal
Part A — Female18161814201412112
Part A — Male810811202629112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per DayTotal
White16141815121612103
Black91178252226108
Asian00110035
American Indian or Alaska Native10010103
Native Hawaiian or Pacific Islander01000001
Multiple00003104
Missing00000000
Region of Enrollment
Region of Enrollment(participants)AGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per DayTotal
United States26262625404041224
Montgomery-Asberg Depression Severity (MADRS) score at baseline (prior to first dose)
Montgomery-Asberg Depression Severity (MADRS) score at baseline (prior to first dose)(units on a scale)AGN-241751 3mg DailyAGN-241751 10mg DailyAGN-241751 25mg DailyPlacebo DailyAGN-241751 3mg Two Times Per DayAGN-241751 25mg Two Times Per DayPlacebo 2 Times Per DayTotal
Mean34.0 ± 4.4835.0 ± 4.5133.3 ± 5.0234.0 ± 4.2034.1 ± 3.6234.2 ± 4.1233.8 ± 5.0534.06 ± 0.509
08

Study locations

5 sites
  • Alea Research
    Phoenix, Arizona 85012, United States
  • Collaborative Neuroscience Network, LLC
    Garden Grove, California 92845, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Hassman Research Institute
    Berlin, New Jersey 08809, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Oct 2019, 11 months.

Results were first posted in Jul 2023, 3 years 8 months after primary completion. A results delay was requested in Oct 2020.

Of 31 phase 1/2 interventional studies under Depressive Disorder, Major, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 75. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2018
First posted
Oct 31, 2018
StartActual
Nov 8, 2018
Primary completionActual
Oct 23, 2019
CompletionActual
Oct 23, 2019
Results delay requested
Oct 23, 2020
Results first posted
Jul 7, 2023
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03726658
Lead sponsor
Syndeio Biosciences, Inc
Responsible party
Sponsor
First posted
Oct 31, 2018
Start date
Nov 8, 2018
Primary completion
Oct 23, 2019
Completion
Oct 23, 2019
Results posted
Jul 7, 2023
Last update
Apr 7, 2026

Study contacts

Ronald M Burch, MD PhD
study director · Syndeio Biosciences, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zelquistinel

Start the discussion